Indeed, tocilizumab, a neutralizing monoclonal antibody that targets the IL-6 receptor (IL-6R), has been reported to be effective for the treatment of uveitis and its associated macular edema (43, 44) and ongoing clinical trials are testing the efficacy of vamikibart, an intravitreal monoclonal antibody targeting IL-6 for the treatment of both, uveitic macular edema and DME (45). Here, IL6 is linked to uveitis.